vincristine sulfate


Korea United Pharma


Concise Prescribing Info
Vincristine sulfate
Acute leukemia. Hodgkin's disease, lymphatic sarcoma, reticulum cell granuloma, rhabdomyosarcoma, neuroblastoma & Wilm's tumor in combination w/ other antineoplastic agents.
Dosage/Direction for Use
Adult 1.4 mg/m2. Childn 2 mg/m2, ≤10 kg Starting dose: 0.05 mg/kg IV given once a wk. Inj should be accomplished w/in 1 min.
Hypersensitivity. Demyelinating form of Charcot-Marie-Tooth syndrome. Pregnancy & lactation.
Special Precautions
Discontinue if extravasation occurs. Patients w/ liver impairment, renal dysfunction, bone marrow suppression, complicating infection, history of neuromuscular disease, chickenpox. Acetic uric acid nephropathy may occur. Consider administration of the next dose in leukopenia or complicating infection. Childn w/ Hodgkin's disease may develop gonadal disorder. Perform CBC prior to administration of each dose. Monitor serum uric acid levels frequently during the first 3-4 wk of treatment. Do not administer intrathecally. Avoid eye contamination.
Adverse Reactions
Alopecia, leukopenia, neuritic pain, constipation, sensory loss, paresthesia, difficulty in walking, slapping gait, loss of deep-tendon reflexes, muscle wasting. Anemia, thrombocytopenia; abdominal cramps, nausea, vomiting, oral ulceration, diarrhea, paralytic ileus, intestinal necrosis & perforation, anorexia; HTN, hypotension; acute shortness of breath, severe bronchospasm; polyuria, dysuria & urinary retention; sensory impairment, foot drop, ataxia, paralysis; jaw pain, pharyngeal pain, parotid gland pain, bone pain, back pain, limb pain, myalgias; convulsions; hyperhidrosis, dermatic exfoliation; transient cortical blindness, optic atrophy; fever, headache, dyslogia, wt reduction.
Drug Interactions
Reduced blood levels of phenytoin & increased seizure activity.
MIMS Class
Cytotoxic Chemotherapy
ATC Classification
L01CA02 - vincristine ; Belongs to the class of plant alkaloids and other natural products, vinca alkaloids and analogues. Used in the treatment of cancer.
Alcavixin soln for inj 1 mg/mL
(Vial) 1 mL x 10 × 1's;2 mL x 10 × 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in